J. Taylor Whaley, MD
Ultima Vez Modificado: 25 de octubre del 2012
Nov 29, 2011 - For patients with low- or intermediate-grade advanced neuroendocrine tumors (carcinoids), everolimus plus octreotide long-acting repeatable (LAR) improves progression-free survival versus placebo plus octreotide LAR, according to a study published online Nov. 25 in The Lancet.
Nov 29, 2011
Jul 24, 2014